Shareholders Foundation, Inc.

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Long Term Investor Alert: Investigation of Potential Wrongdoing

An investigation on behalf of current long term investors in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) shares over possible breaches of fiduciary duty by certain officers and directors was announced and NASDAQ:ICPT stockholders should contact the Shareholders Foundation.

 

San Diego, CA -- (SBWIRE) -- 02/24/2021 -- An investigation on behalf of current long-term investors in shares of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) concerning potential breaches of fiduciary duties by certain directors and officers of Intercept Pharmaceuticals, Inc. was announced.

Investors who are current long term investors in Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm for current long term investors in (NASDAQ: ICPT stocks follows a lawsuit filed against Intercept Pharmaceuticals, Inc. over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ: ICPT stocks, concerns whether certain Intercept Pharmaceuticals, Inc. directors are liable in connection with the allegations made in that lawsuit.

According to that complaint filed in the U.S. District Court for the Eastern District of New York the plaintiff alleges that, the Defendants made false and/or misleading statements and/or failed to disclose that the Defendants downplayed the true scope and severity of safety concerns associated with Ocaliva's use in treating PBC, that the foregoing increased the likelihood of an FDA investigation into Ocaliva's development, thereby jeopardizing Ocaliva's continued marketability and the sustainability of its sales, that any purported benefits associated with OCA's efficacy in treating NASH were outweighed by the risks of its use, that as a result, the FDA was unlikely to approve the Company's NDA for OCA in treating patients with liver fibrosis due to NASH, and that as a result of all the foregoing, the Company's public statements were materially false and misleading at all relevant times.

Those who purchased shares of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.